Blood Screening Market: Global Market Size, Growth factors, Dynamics, Regional Share, Trends, Top Key Players, Competitor Analysis 2017 to 2021 and Forecast 2022 to 2028

$ PRICE - $ 3,000.00$ 8,900.00

Blood Screening Market by Product (Instrument, Reagents & Kits and Software), By Technology (Nucleic Acid Amplification, Elisa, Rapid test, NGS, and Western Blotting), By End user (Blood banks and Hospitals) and Geography

 

$ PRICE - $ 3,000.00$ 8,900.00
Clear selection
Clear
$ PRICE - $ 3,000.00$ 8,900.00
FacebookTwitterLinkedinEmail
SKU: N/A Category:

Report

Description

Blood Screening Market size is valued at USD 2,225 million in 2021 and is expected to grow at a CAGR of 8.6% during the forecast period 2022 to 2028. Blood screening is defined as various tests done on blood samples for the diagnosis of numerous diseases such as AIDS, syphilis, hepatitis treatment, and other clinical circumstances such as pregnancy. It aids in monitoring diseases and avoiding health issues and a variety of other conditions such as cancer and infections. Blood donor screening is the protection mechanism employed against the spread of infection before blood donation. The global market provides a detailed overview of the Blood Screening market, and that can be segmented by product, by technology, and by end user. By product, the Blood Screening market has been segmented into Instrument, Reagents & Kits, and Software. The reagents & kits segment is likely to be the largest and fastest-growing segment in terms of product. The rise of this segment is mainly due to an increase in blood transfusion events, because of which there is more repeated use and consumption of reagents & kits in blood screening process. Based on Technology, the Nucleic Acid Amplification, Elisa, Rapid test, NGS, and Western Blotting. Among these, the Nucleic Acid Amplification segment is expected to have the fastest-growing market during the forecast period 2022-2028. The major factor for rising of this segment is the growing acceptance of nucleic acid amplification technology due to its increased sensitivity over other blood screening techniques. Apart from this, the increasing number of blood donations can also drive the growth of this segment. Based on the End user, the Blood Screening market is segmented into Blood banks and Hospitals. The Blood banks segment is expected to have a significant share in 2021. The rise of this segment is mainly because of the increasing number of organ transplants.

Key Developments:

In September 2021, Roche Diagnostics acquired TIB Molbiol Group to expand its business in molecular diagnostics.

In February 2020, BD (US) acquired NAT Diagnostics (US), to enhance a molecular diagnostic platform for POC testing.

Blood Screening Market

MARKET SUMMARY
-
8.6% CAGR
  • Study Period– 2021 – 2027
  • Base Year– 2020
  • CAGR– 8.6%
  • Largest Market– North America
  • Fastest Growing Market– Europe

Blood Screening Market

  • The blood screening market report gives comprehensive outlook across the region with special emphasis on key regions such as North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • The blood screening market is segmented based on product, technology, end user and geography.
Key Players
  • Becton, Dickinson and Company
  • Thermo Fisher Scientific Inc.
  • Danaher Corporation
  • Abbott Laboratories
  • Bio-Rad Laboratories Inc.
Blood Screening Market Drivers

The increasing incidence rate of infectious diseases is anticipated to propel market growth over the forecast years. Moreover, the growing awareness about blood donation and the protection of donated blood are burgeoning the market growth over the forecast years.


North American Got Significant Share

Blood Screening Market

North American market is expected to witness the highest market share during the forecast period

Latin America
Latin-America
North-America
North-America
Europe
Europe
Asia Pacific
Asia-Pacific
Middle East
Middle East

Key

Features of the Report

  • The Blood screening market provides granular level information about the market size, regional market share, historic market (2017-2021) and forecast (2022-2028)
  • The Blood screening market covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The Blood screening market outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The Blood screening market tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The Blood screening market provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
Blood Screening Market Segmentation


Location

GEOGRAPHY

Frequently Asked Questions

The blood screening market is projected to expand at a CAGR of 8.6% during the forecast period

Becton, Dickinson and Company, Thermo Fisher Scientific Inc., Danaher Corporation, Abbott Laboratories, Bio-Rad Laboratories Inc., Grifols, Siemens AG, Beckman Coulter Inc.

North American is the fastest-growing region for blood screening market


Report

Table Of Content


Report

Company Profile

  • Becton, Dickinson and Company
  • Thermo Fisher Scientific Inc.
  • Danaher Corporation
  • Abbott Laboratories
  • Bio-Rad Laboratories Inc.
  • Grifols
  • Siemens AG
  • Beckman Coulter Inc.

Description

Blood Screening Market size is valued at USD 2,225 million in 2021 and is expected to grow at a CAGR of 8.6% during the forecast period 2022 to 2028. Blood screening is defined as various tests done on blood samples for the diagnosis of numerous diseases such as AIDS, syphilis, hepatitis treatment, and other clinical circumstances such as pregnancy. It aids in monitoring diseases and avoiding health issues and a variety of other conditions such as cancer and infections. Blood donor screening is the protection mechanism employed against the spread of infection before blood donation. The global market provides a detailed overview of the Blood Screening market, and that can be segmented by product, by technology, and by end user. By product, the Blood Screening market has been segmented into Instrument, Reagents & Kits, and Software. The reagents & kits segment is likely to be the largest and fastest-growing segment in terms of product. The rise of this segment is mainly due to an increase in blood transfusion events, because of which there is more repeated use and consumption of reagents & kits in blood screening process. Based on Technology, the Nucleic Acid Amplification, Elisa, Rapid test, NGS, and Western Blotting. Among these, the Nucleic Acid Amplification segment is expected to have the fastest-growing market during the forecast period 2022-2028. The major factor for rising of this segment is the growing acceptance of nucleic acid amplification technology due to its increased sensitivity over other blood screening techniques. Apart from this, the increasing number of blood donations can also drive the growth of this segment. Based on the End user, the Blood Screening market is segmented into Blood banks and Hospitals. The Blood banks segment is expected to have a significant share in 2021. The rise of this segment is mainly because of the increasing number of organ transplants.

Key Developments:

In September 2021, Roche Diagnostics acquired TIB Molbiol Group to expand its business in molecular diagnostics.

In February 2020, BD (US) acquired NAT Diagnostics (US), to enhance a molecular diagnostic platform for POC testing.

ASIA PACIFIC OFFICE

Precision Business Insights, MIG 366, SAI PLAZA, 1st Floor, KPHB Colony, Hyderabad - 500072

EUROPE OFFICE

Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX